The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda.

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent's sintilimab last year, and a new trial in lung cancer will raise its hopes of getting ...